Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

Ads

You May Also Like

Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent

BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a ...

HDAC Inhibitors Market, 2026

Dublin, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition ...

Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; ...